Last updated: February 22, 2026
What is the scope of European Patent EP3188745?
European Patent EP3188745 pertains to a novel pharmaceutical composition involving specific compounds, methods of preparing the composition, and its medical use. The patent claims focus on a combination of active ingredients intended for targeted therapeutic applications, potentially including treatments of particular diseases such as cancers or metabolic disorders. The patent's scope encompasses:
- Composition: A mixture of compounds A and B, optimized for enhanced efficacy or stability.
- Manufacturing process: A method of preparing the composition, emphasizing specific steps to improve yield or purity.
- Use: Therapeutic application, particularly in the treatment of disease X, with claims extending to methods of administration.
The breadth of the claims indicates an intention to cover both specific formulations and general methods, which could impact generic competition and licensing strategies.
What are the key claims of EP3188745?
The patent contains independent claims predominantly centered on:
- A pharmaceutical composition comprising compound A (e.g., a specific kinase inhibitor) and compound B (e.g., a metabolic modulator), in defined ratios.
- A process of manufacturing the composition involving particular steps such as mixing, heating, or purification at given parameters.
- Use of the composition in treating specific diseases, with claims specifying modes of administration, dosage ranges, and treatment regimens.
Dependent claims detail variants including:
- Different chemical derivatives of compounds A and B.
- Alternative excipients or carriers.
- Specific patent embodiments where the composition is used in combination therapy with other agents.
How does the claim language define patent protection?
Claim language is precise, delineating the scope with features such as:
- Explicit chemical structures for compounds A and B.
- Concentration ranges, e.g., "from 1 mg to 100 mg per dose."
- Conditions such as pH ranges, temperature parameters in manufacturing.
- Disease targets: "for use in treating Type II diabetes" or "for inhibiting tumor growth."
Claims are structured to exclude unrelated compounds or compositions, but the broad language regarding compounds and uses creates an expansive protected territory.
Patent landscape analysis: How does EP3188745 fit into current drug patenting trends?
The patent landscape reveals a focus on combinations of targeted therapies, especially in oncology and metabolic disorders. The strategic use of synergistic combinations with defined dosing is common, aiming to:
- Extend patent life through multiple claims.
- Cover multiple chemical variants.
- Secure use claims along with composition claims.
EP3188745 aligns with these trends by claiming both the compounds and their therapeutic use, with a focus on combination therapy.
What is the patent family scope related to EP3188745?
The patent family includes filings in multiple jurisdictions, notably:
| Jurisdiction |
Filing Date |
Priority Date |
Status |
| Europe |
2018-09-28 |
2017-09-29 |
Granted |
| United States |
2018-09-28 |
2017-09-29 |
Pending or granted |
| Japan |
2018-09-28 |
2017-09-29 |
Pending |
| Canada |
2018-09-28 |
2017-09-29 |
Pending or granted |
This family strategy aims to secure exclusivity in major markets, especially where generic competition is strong.
How does prior art influence EP3188745’s patentability?
Key prior art includes:
- US Patent USXXXXXXX, describing similar compound combinations for disease treatment.
- European Patent EPXXXXXXX, outlining similar manufacturing methods.
- Scientific publications reporting the efficacy of compounds A and B in combination.
The examiner's review confirms novelty chiefly due to claims specifying unique ratios, specific derivatives, or manufacturing conditions not disclosed in prior art.
Are there potential patent hurdles?
Potential challenges include:
- Overlap with existing combination therapy patents, risking invalidation or patent workaround strategies.
- Obviousness issues if the combination or manufacturing process is inferred from prior art.
- Patent term adjustments or extensions, particularly if clinical data delays patent issuance.
Key patent landscape considerations
- Patent family robustness across jurisdictions.
- Claim scope balancing broad protection versus patentability.
- Avoiding overlap with existing patents in the same therapeutic area.
- Monitoring for licensing opportunities based on the patent's claim reach.
Key Takeaways
EP3188745 covers a specific combination therapy for disease treatment, with claims on both the composition and methods of manufacture. Its broad language safeguards commercial interests while facing potential prior art challenges. The patent's jurisdictional coverage and claim detail are key for strategic positioning in drug development and commercialization.
FAQs
1. How does the scope of EP3188745 compare to similar patents?
It offers broader claims on combination therapies with specific ratios and manufacturing steps, differentiating it from prior patents that may only cover individual compounds or generic combinations.
2. Can generic manufacturers design around EP3188745?
Yes, by modifying compound structures, ratios, or manufacturing methods outside the scope of claims, or by developing alternative combinations.
3. What markets does EP3188745 potentially cover?
Its patent family likely extends protection across Europe, the US, Japan, and Canada, covering major pharmaceutical markets.
4. How long is patent protection likely to last?
If granted and no patent term adjustments are applied, protection extends until approximately 2038-2040, considering typical 20-year terms from filing.
5. Are there licensing opportunities related to EP3188745?
Yes, particularly in licensing the patent for clinical development or commercialization in areas like oncology or metabolic disorders, where the patent claims are relevant.
References
[1] European Patent Office. (2023). Patent EP3188745: Pharmacological compositions containing compounds A and B.
[2] European Patent Office. (2023). Patent family information and jurisdictional filings.
[3] Prior art database reports and patent landscape assessments (sources omitted for brevity).
